TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Neuromod Devices appointed Joe Ghiz as chief commercial officer and Shannon Basham as vice president of channel development, the Dublin-based company announced Oct. 1, 2026. The hires bring commercial and hearing-care experience as Neuromod seeks to expand access to its Lenire tinnitus device; the company did not announce specific sales targets or a rollout timetable.
Neuromod Devices appointed Joe Ghiz as chief commercial officer and Shannon Basham as vice president of channel development, the Dublin-based medical technology company announced Oct. 1, 2026. The appointments add senior commercial and hearing-care expertise as Neuromod seeks to expand global access to Lenire, its device-based tinnitus treatment.
Ghiz joins Neuromod from Align Technology, the company behind Invisalign, where he served as general manager of sales and held other global commercial leadership positions. Earlier, he spent more than a decade at Johnson & Johnson Vision Care in roles covering sales, marketing and business development. Neuromod said Ghiz will lead its global commercial function and help position Lenire for use in ENT and audiology practices.
Basham brings more than 20 years in hearing care. Most recently, she was senior director of audiology for Sonova Group in the United States, serving as the market-facing head of audiology for its Phonak and Unitron wholesale businesses. Her remit included strategy and leadership for audiology and clinical education. Before that, she spent a decade directing clinical training at Phonak, overseeing training and education programs across its product lines.
Neuromod also cited Basham’s earlier work as clinical training manager at Insound Medical, where she helped commercialize and scale the Lyric hearing aid. The company said that effort supported Insound’s acquisition by Sonova. The appointments place commercial leadership and channel development under two executives with experience in medical technology, hearing-care products and professional education.
How the Hires Could Expand Lenire Access
The appointments point to Neuromod’s focus on commercial growth and clinician access for Lenire, rather than a change to the device or its stated treatment approach. Ghiz’s remit covers the company’s global commercial function, while Basham’s channel-development role draws on experience working with audiology businesses and clinical education. Those areas can matter for a prescribed device that depends on clinician involvement.
Neuromod says it wants Lenire to become a standard of care for tinnitus in ENT and audiology practices. That is the company’s objective, not an established clinical or market outcome. The new hires may help it develop commercial relationships and reach more clinicians, but the announcement does not provide targets, timelines, or evidence that these appointments will change adoption rates.
For patients and providers, the practical relevance is whether efforts to expand access lead to wider availability through qualified clinicians and the channels where hearing care is delivered. The announcement itself does not detail changes to prescribing, treatment, pricing or eligibility.
As an affiliate, we earn on qualifying purchases.
Lenire’s Prescribed At-Home Treatment
Neuromod describes Lenire as a non-invasive bimodal neuromodulation device combining audio stimulation with stimulation delivered to the surface of the tongue through a component trademarked Tonguetip. According to the company’s description, an ENT or audiologist prescribes it after an audiological examination, and patients complete treatment at home.
The company says Lenire has CE-mark certification and received a De Novo Approval Grant from the US Food and Drug Administration. It is available in the United States, Canada, Europe and Australia, and is also a treatment option through the US Veterans Affairs system, according to the supplied company information. Neuromod has offices in Ireland and North America.
In the announcement, CEO Dr Ross O’Neill linked the hires to what he described as clinical evidence, regulatory approvals and commercial adoption. The company’s stated goal of scaling access builds on those existing authorizations and markets; the announcement does not report a new regulatory decision or a change in Lenire’s indication.
“We are delighted to welcome Joe Ghiz to Neuromod at a pivotal moment.”
— Dr Ross O’Neill, Neuromod CEO
neuromodulation device for tinnitus
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Targets and Rollout Plans Not Disclosed
The announcement does not specify commercial targets, hiring plans, market-by-market priorities or a timetable for expanding Lenire access. It also does not describe changes to the device, its price, prescribing process or availability in the markets named by the company.
Neuromod’s statements about patient impact, clinical evidence and the potential for wider adoption are company claims. The supplied material does not include independent verification, detailed outcome figures or a breakdown of adoption by market. It is also unclear how the responsibilities of Ghiz and Basham will be divided in specific regions or across clinician and distribution channels.
As an affiliate, we earn on qualifying purchases.
Commercial Strategy Under New Leaders
Ghiz is expected to lead Neuromod’s global commercial function, while Basham will oversee channel development. The company has not announced a first milestone or schedule for either role. Further details may emerge through company updates about partnerships, clinician outreach, market availability or adoption, but none of those developments was specified in the Oct. 1 announcement.
For now, the confirmed change is the addition of two senior executives to support Neuromod’s stated growth plans. Whether that produces broader access to Lenire will depend on subsequent commercial decisions and implementation, details of which remain undisclosed.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who did Neuromod appoint?
Joe Ghiz was named chief commercial officer, and Shannon Basham was named vice president of channel development. Neuromod announced the appointments on Oct. 1, 2026.
What will Ghiz do at Neuromod?
Neuromod said Ghiz will lead its global commercial function as it works to expand access to Lenire and position the device for use in ENT and audiology practices.
What experience does Basham bring?
Basham has more than 20 years of hearing-care experience, including senior audiology and clinical education roles at Sonova and Phonak, according to Neuromod’s announcement.
What is Lenire?
Neuromod describes Lenire as a non-invasive tinnitus treatment device that combines audio stimulation with stimulation to the surface of the tongue. The company says it is prescribed by an ENT or audiologist after an audiological examination, with treatment completed at home.
Did Neuromod announce a rollout timetable?
No. The announcement did not give a commercial timetable, sales target or market-by-market plan for expanding Lenire access.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
